

Kenji Watanabe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4206329/publications.pdf>

Version: 2024-02-01

72
papers

2,676
citations

257357

24
h-index

197736

49
g-index

79
all docs

79
docs citations

79
times ranked

2839
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial. <i>Intestinal Research</i> , 2023, 21, 110-125.	1.0	9
2	Potential benefits of immunomodulator use with vedolizumab for maintenance of remission in ulcerative colitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 81-88.	1.4	6
3	A review on the current status and definitions of activity indices in inflammatory bowel disease: how to use indices for precise evaluation. <i>Journal of Gastroenterology</i> , 2022, 57, 246-266.	2.3	22
4	AJM300 (carotegrast methyl), an oral antagonist of β_4 -integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 648-657.	3.7	38
5	Notable gaps between patients' and physicians' perspectives on communication and disease management in Japan: multifaceted <i>ad hoc</i> analyses of the global Ulcerative Colitis Narrative Survey for further optimal care. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482210953.	1.4	3
6	A Prospective Study Evaluating the Clinical Utility of the Tag-Less Patency Capsule with Extended Time for Confirming Functional Patency. <i>Digestion</i> , 2021, 102, 180-187.	1.2	8
7	Tag-less patency capsule for suspected small bowel stenosis: Nationwide multicenter prospective study in Japan. <i>Digestive Endoscopy</i> , 2021, 33, 151-161.	1.3	17
8	Association of Dietary Fatty Acid Intake With the Development of Ulcerative Colitis: A Multicenter Case-Control Study in Japan. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 617-628.	0.9	8
9	Does anti-tumor necrosis factor alpha prevent the recurrence of Crohn's disease? Systematic review and meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 864-872.	1.4	7
10	Intestinal cancer in patients with Crohn's disease: A systematic review and meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 329-336.	1.4	15
11	Concomitant use of an immunomodulator with ustekinumab as an induction therapy for Crohn's disease: A systematic review and meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1744-1753.	1.4	5
12	Ulcerative Colitis Narrative Global Survey Findings: The Impact of Living With Ulcerative Colitis—Patients' and Physicians' View. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1747-1755.	0.9	21
13	Potential problems of partial resection for colitis-associated cancer in a patient with ulcerative colitis: case report. <i>Journal of Surgical Case Reports</i> , 2021, 2021, rjab086.	0.2	0
14	The impact of cytochrome P450 3A genetic polymorphisms on tacrolimus pharmacokinetics in ulcerative colitis patients. <i>PLoS ONE</i> , 2021, 16, e0250597.	1.1	4
15	Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. <i>Journal of Gastroenterology</i> , 2021, 56, 489-526.	2.3	202
16	Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study. <i>Journal of Gastroenterology</i> , 2021, 56, 560-569.	2.3	34
17	Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 429-437.	3.7	34
18	655 Association between Crohn's disease onset and oral hygiene: a Japanese multicenter case-control study. <i>International Journal of Epidemiology</i> , 2021, 50, .	0.9	0

#	ARTICLE	IF	CITATIONS
19	Week 2 Symptomatic Response with Vedolizumab as a Predictive Factor in Japanese Anti-TNF±-Naive Patients with Ulcerative Colitis: A post hoc Analysis of a Randomized, Placebo-Controlled Phase 3 Trial. <i>Digestion</i> , 2021, 102, 742-752.	1.2	8
20	A nationwide survey concerning the mortality and risk of progressing severity due to arterial and venous thromboembolism in inflammatory bowel disease in Japan. <i>Journal of Gastroenterology</i> , 2021, 56, 1062-1079.	2.3	5
21	OUP accepted manuscript. <i>Journal of Crohn's and Colitis</i> , 2021, , .	0.6	6
22	Indigo naturalis is effective even in treatment-refractory patients with ulcerative colitis: a post hoc analysis from the INDIGO study. <i>Journal of Gastroenterology</i> , 2020, 55, 169-180.	2.3	23
23	Significance of Conducting 2 Types of Fecal Tests in Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1102-1111.e5.	2.4	29
24	Efficacies and Related Issues of Ustekinumab in Japanese Patients with Crohn's Disease: A Preliminary Study. <i>Digestion</i> , 2020, 101, 53-59.	1.2	15
25	Effects of vedolizumab in Japanese patients with Crohn's disease: a prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analyses. <i>Journal of Gastroenterology</i> , 2020, 55, 291-306.	2.3	34
26	Efficacy of apheresis as maintenance therapy for patients with ulcerative colitis in an open-label prospective multicenter randomised controlled trial. <i>Journal of Gastroenterology</i> , 2020, 55, 390-400.	2.3	14
27	Clinical relevance of innovative immunoassays for serum ustekinumab and anti-ustekinumab antibody levels in Crohn's disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1163-1170.	1.4	9
28	Long-Term Follow-Up of Targeted Biopsy Yield (LOFTY Study) in Ulcerative Colitis Surveillance Colonoscopy. <i>Journal of Clinical Medicine</i> , 2020, 9, 2286.	1.0	7
29	Evidence-based diagnosis and clinical practice guidelines for intestinal Behçet's disease 2020 edited by Intractable Diseases, the Health and Labour Sciences Research Grants. <i>Journal of Gastroenterology</i> , 2020, 55, 679-700.	2.3	39
30	The shining DIAMOND for evidence-based treatment strategies for Crohn's disease. <i>Journal of Gastroenterology</i> , 2020, 55, 824-832.	2.3	1
31	Clinical Characteristics and Risk Factors for <i>Pneumocystis Jirovecii</i> Pneumonia during Immunosuppressive Treatment in Patients with Ulcerative Colitis: A Retrospective Study. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 29, 167-173.	0.5	8
32	Clinical management for small bowel of Crohn's disease in the treat-to-target era: now is the time to optimize treatment based on the dominant lesion. <i>Intestinal Research</i> , 2020, 18, 347-354.	1.0	22
33	Middle-term prognosis in patients with ulcerative colitis who achieved clinical and endoscopic remission by budesonide rectal foam. <i>PLoS ONE</i> , 2019, 14, e0220413.	1.1	6
34	The association between environmental factors and the development of Crohn's disease with focusing on passive smoking: A multicenter case-control study in Japan. <i>PLoS ONE</i> , 2019, 14, e0216429.	1.1	14
35	Endoscopic diagnosis and treatment of ulcerative colitis-associated neoplasia. <i>Digestive Endoscopy</i> , 2019, 31, 26-30.	1.3	10
36	Withdrawal of thiopurines in Crohn's disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2). <i>Journal of Gastroenterology</i> , 2019, 54, 860-870.	2.3	21

#	ARTICLE	IF	CITATIONS
37	Concerns and Side Effects of Azathioprine During Adalimumab Induction and Maintenance Therapy for Japanese Patients With Crohn's Disease: A Subanalysis of a Prospective Randomised Clinical Trial [DIAMOND Study]. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1097-1104.	0.6	15
38	Wedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study. <i>PLoS ONE</i> , 2019, 14, e0212989.	1.1	59
39	Capsule endoscopy findings for the diagnosis of Crohn's disease: a nationwide case-control study. <i>Journal of Gastroenterology</i> , 2019, 54, 249-260.	2.3	22
40	Measurement of prostaglandin metabolites is useful in diagnosis of small bowel ulcerations. <i>World Journal of Gastroenterology</i> , 2019, 25, 1753-1763.	1.4	17
41	Combined Infection of Human Herpes Viruses: A Risk Factor for Subsequent Colectomy in Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1307-1315.	0.9	15
42	Evidence-based clinical practice guidelines for inflammatory bowel disease. <i>Journal of Gastroenterology</i> , 2018, 53, 305-353.	2.3	427
43	Clinical and Pharmacokinetic Factors Associated With Adalimumab-Induced Mucosal Healing in Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 542-549.e1.	2.4	40
44	Efficacy of Indigo Naturalis in a Multicenter Randomized Controlled Trial of Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2018, 154, 935-947.	0.6	139
45	Inflammatory bowel disease patients experiencing a loss of response to infliximab regain long-term response after undergoing granulocyte/monocyte apheresis: A case series. <i>Cytokine</i> , 2018, 103, 25-28.	1.4	17
46	Efficacy of Endoscopic Balloon Dilation for Small Bowel Strictures in Patients With Crohn's Disease: A Nationwide, Multi-centre, Open-label, Prospective Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 394-401.	0.6	56
47	Endoscopic submucosal dissection for nonpolypoid colorectal dysplasia in patients with inflammatory bowel disease: in medias res. <i>Gastrointestinal Endoscopy</i> , 2018, 87, 1085-1094.	0.5	29
48	Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study. <i>Journal of Gastroenterology</i> , 2018, 53, 494-506.	2.3	20
49	Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab: CERISIER trial. <i>Intestinal Research</i> , 2018, 16, 494.	1.0	20
50	Usefulness of fecal calprotectin by monoclonal antibody testing in adult Japanese with inflammatory bowel diseases: a prospective multicenter study. <i>Intestinal Research</i> , 2018, 16, 554-562.	1.0	4
51	Predicting outcomes to optimize disease management in inflammatory bowel disease in Japan: their differences and similarities to Western countries. <i>Intestinal Research</i> , 2018, 16, 168.	1.0	8
52	Clinical Practice Guideline for Enteroscopy. <i>Digestive Endoscopy</i> , 2017, 29, 519-546.	1.3	117
53	The 5C Concept and 5S Principles in Inflammatory Bowel Disease Management. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1302-1308.	0.6	12
54	Sleep disturbances in Japanese patients with inflammatory bowel disease and their impact on disease flare. <i>SpringerPlus</i> , 2016, 5, 1792.	1.2	25

#	ARTICLE	IF	CITATIONS
55	Comparison of Targeted vs Random Biopsies for Surveillance of Ulcerative Colitis-Associated Colorectal Cancer. <i>Gastroenterology</i> , 2016, 151, 1122-1130.	0.6	171
56	Adalimumab Monotherapy and a Combination with Azathioprine for Crohn's Disease: A Prospective, Randomized Trial. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 1259-1266.	0.6	182
57	Twice-daily Budesonide 2-mg Foam Induces Complete Mucosal Healing in Patients with Distal Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 828-836.	0.6	42
58	Clinical impact of ultrathin colonoscopy for Crohn's disease patients with strictures. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 66-70.	1.4	9
59	A Hereditary Enteropathy Caused by Mutations in the <i>SLCO2A1</i> Gene, Encoding a Prostaglandin Transporter. <i>PLoS Genetics</i> , 2015, 11, e1005581.	1.5	94
60	Factors associated with treatment outcome, and long-term prognosis of patients with ulcerative colitis undergoing selective depletion of myeloid lineage leucocytes: a prospective multicenter study. <i>Cytotherapy</i> , 2015, 17, 680-688.	0.3	28
61	Safety and Efficacy of AJM300, an Oral Antagonist of $\alpha 4$ Integrin, in Induction Therapy for Patients With Active Ulcerative Colitis. <i>Gastroenterology</i> , 2015, 149, 1775-1783.e2.	0.6	120
62	Use of capsule endoscopy in patients with Crohn's disease in Japan: A multicenter survey. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 96-101.	1.4	39
63	Precise Endoscopic and Pathologic Features in a Crohn's Disease Case with Two Fistula-associated Small Bowel Adenocarcinomas Complicated by an Anal Canal Adenocarcinoma. <i>Internal Medicine</i> , 2013, 52, 445-449.	0.3	10
64	Dermokine expression in intraductal papillary-mucinous neoplasm and invasive pancreatic carcinoma. <i>Anticancer Research</i> , 2012, 32, 4405-12.	0.5	6
65	Wireless capsule endoscopy in pediatric patients: the first series from Japan. <i>Journal of Gastroenterology</i> , 2010, 45, 683-691.	2.3	36
66	Endoscopic and chromoendoscopic atlas featuring dysplastic lesions in surveillance colonoscopy for patients with long-standing ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 259-264.	0.9	42
67	Evaluation of Deep Small Bowel Involvement by Double-Balloon Enteroscopy in Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2006, 101, 1484-1489.	0.2	142
68	Intracranial Extension of an Orbital Pseudotumor Accompanied by Internal Carotid Artery Occlusion – Case Report. <i>Neurologia Medico-Chirurgica</i> , 1992, 32, 758-761.	1.0	4
69	A CASE REPORT OF CAROTID BODY TUMOR. <i>The Journal of the Japanese Practical Surgeon Society</i> , 1990, 51, 60-63.	0.0	0
70	A CASE OF MALIGNANT MELANOMA OF THE RECTUM. <i>The Journal of the Japanese Practical Surgeon Society</i> , 1988, 49, 888-891.	0.0	0
71	A CASE OF SPLENIC ABSCESS UNKNOWN ORIGIN. <i>The Journal of the Japanese Practical Surgeon Society</i> , 1988, 49, 112-115.	0.0	0
72	A CASE OF ADENOSQUAMOUS CARCINOMA OF THE SIGMOID COLON. <i>The Journal of the Japanese Practical Surgeon Society</i> , 1988, 49, 690-695.	0.0	2